Xcout IntelCytosorbents Corporation
Cytosorbents Corporation specializes in creating and bringing to market innovative medical devices. Their core expertise lies in a unique blood purification platform, built upon a proprietary adsorbent and porous polymer technology. The company's leading product, CytoSorb, is an extracorporeal filter designed to remove cytokines from the blood. It serves as a complementary treatment in various critical care scenarios, including sepsis, managing complications during and after heart bypass surgery, and improving the viability of donor organs for transplantation. Beyond CytoSorb, Cytosorbents offers a portfolio of specialized devices. These include VetResQ, used to assist in treating critical conditions like sepsis and pancreatitis in animals; CytoSorb-XL, another device targeting sepsis and other severe illnesses; HemoDefend, a platform for purifying blood supplies by removing contaminants that cause transfusion reactions and diseases, as well as anti-A and anti-B antibodies from blood products; K+ontrol, designed for patients with severe, life-threatening hyperkalemia; and ContrastSorb, which extracts intravenous contrast agents following imaging procedures (like CT scans, angiograms, or interventional radiology) to mitigate the risk of contrast-induced kidney damage. The company is also actively developing several new solutions: BetaSorb, aimed at preventing and treating complications from metabolic toxin buildup in chronic kidney disease patients; DrugSorb, which focuses on eliminating harmful chemicals from the bloodstream; and DrugSorb-ATR, an innovative system for removing antithrombotic agents. Originally established as MedaSorb Technologies Corporation in 1997, the company adopted its current name, Cytosorbents Corporation, in May 2010. Its corporate headquarters are situated in Princeton, New Jersey.
Subscribe to see Cytosorbents Corporation’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Cytosorbents Corporation at a glance
Cytosorbents Corporation is a medical devices company headquartered in Princeton, United States. It is publicly listed (CTSO) with a market capitalisation of $11.3M. Xcout tracks 18 named people at Cytosorbents Corporation, including Phillip Chan (Chief Executive Officer & Director).
Cytosorbents Corporation leadership
- Phillip ChanChief Executive Officer & Director
- Phillip P. ChanChief Executive Officer
- Vincent J. CapponiPresident & Chief Operating Officer
- Peter J. MarianiChief Financial Officer
- Efthymios N. Deliargyris FACC FESC FSCAIChief Medical Officer
- Robert H. BartlettCo-Chairman of Cardiac Surgery Advisory Board & Consultant
12 more named people on record for Cytosorbents Corporation, with roles, board committees and tenure — see the full roster →
Cytosorbents Corporation competitors
A few of Cytosorbents Corporation's closest competitors — see the full list of competitors and alternatives →
SeaStar Medical Holding Corporation is a medical device company dedicated to providing innovative solutions and services designed to combat hyperinflammation and cytokine storm in critically ill individuals. The company specializes in developing and commercializing extracorporeal therapies that specifically target the immune 'effector cells' responsible for driving systemic inflammation, a process that directly harms tissues and releases a cascade of pro-inflammatory cytokines, thereby initiating and perpetuating dysregulated immune reactions. Its product pipeline spans various critical care areas, including acute kidney injury (both pediatric and adult) requiring continuous renal replacement therapy (CRRT), cardiorenal syndrome in patients with congestive heart failure (including those with or without LVADs), myocardial stunning in end-stage renal disease, and hepatorenal syndrome. The firm maintains its headquarters in Denver, Colorado.
Cerus Corporation operates as a biotechnology firm dedicated to advancing and marketing the INTERCEPT Blood System. This proprietary technology significantly enhances the safety of transfusable blood components by neutralizing biological threats, thereby reducing the risk of blood-borne pathogens. The company's product line includes INTERCEPT systems specifically engineered to deactivate pathogens in donated platelets and plasma. It also offers a dedicated INTERCEPT Blood System for the inactivation of harmful agents in red blood cell components. Furthermore, Cerus markets an INTERCEPT Blood System for Cryoprecipitation, which leverages its plasma technology to produce two key pathogen-reduced blood products: a cryoprecipitated fibrinogen complex for treating and controlling bleeding, particularly massive hemorrhages stemming from fibrinogen deficiency, and pathogen-reduced, cryoprecipitate-reduced plasma. Cerus distributes these platelet and plasma systems globally through a combination of its direct sales force and an extensive network of distributors, reaching markets in North America, Europe, the Commonwealth of Independent States, the Middle East, and Latin America. Established in 1991, Cerus Corporation maintains its corporate headquarters in Concord, California.
Aethlon Medical, Inc. operates as a medical technology enterprise, dedicated to innovating solutions for the diagnosis and treatment of life-threatening and organ-jeopardizing diseases within the United States. Central to its pipeline is the Aethlon Hemopurifier, a clinical-stage immunotherapeutic device. This device is engineered to clear the human circulatory system of detrimental tumor-derived exosomes and perilous viruses. Notably, this capability extends to targeting the COVID-19 virus, its various strains, and associated exosomes. Furthermore, Aethlon Medical maintains a collaborative partnership with the University of Pittsburgh Medical Center's Hillman Cancer Center, conducting studies pertinent to head and neck cancer. Established in 1999, the company is headquartered in San Diego, California.
Glycorex Transplantation AB develops medical devices that utilize proprietary technology to selectively remove specific antibodies from the blood. Its core product, Glycosorb® ABO, enables blood group incompatible organ, stem cell, and heart transplants. Additionally, the company is expanding its applications to include universal blood plasma production and treatments for autoimmune diseases such as rheumatoid arthritis.
Quanta Dialysis Technologies is a medical-device company that develops hemodialysis systems, notably its compact SC+ platform. Its products are intended for use by dialysis providers and healthcare professionals in clinical and home-care settings to treat patients with kidney failure.
Xeltis is a medical technology company that develops bioresorbable cardiovascular implants, such as artificial blood vessels and valves. Utilizing its proprietary Restorex technology, the company's products are designed to be gradually replaced by the patient's own living tissue to treat life-threatening conditions and improve vascular surgery outcomes.
Get Cytosorbents Corporation's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Cytosorbents Corporation in Xcout Intel
- 18 named people with titles, LinkedIn and board committees
- 2 corporate events with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access